Replies to post #218013 on Biotech Values

[DewDiligence]

PRTA +9% on BMY’s opt-in_for_anti-tau_compound, PRX005:

https://finance.yahoo.com/news/prothena-announces-bristol-myers-squibb-123000524.html

PRTA gets $80M from BMY for the opt-in and is eligible to receive as much as $2.2B in regulatory/commercial milestone payments.

BMY inherited this collaboration from CELG (#msg-139431013).